AAV-based vectors for human diseases modeling in laboratory animals
The development of therapeutic drugs and vaccines requires the availability of appropriate model animals that replicate the pathogenesis of human diseases. Both native and transgenic animals can be utilized as models. The advantage of transgenic animals lies in their ability to simulate specific pro...
Saved in:
| Main Authors: | Timur I. Aliev, Dmitry V. Yudkin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1499605/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Use of AAV Vector-based Gene Therapy in the Treatment of Ophthalmic Diseases. Literature Review
by: Z. A. Batyrova, et al.
Published: (2025-06-01) -
Investigating the In Vivo Effects of Anti-Prion Protein Nanobodies on Prion Disease with AAV Vector
by: Jingjing Zhang, et al.
Published: (2025-02-01) -
Recombinant AAV batch profiling by nanopore sequencing elucidates product-related DNA impurities and vector genome length distribution
by: Florian Dunker-Seidler, et al.
Published: (2025-03-01) -
In vivo applications and toxicities of AAV-based gene therapies in rare diseases
by: Qian Zhao, et al.
Published: (2025-07-01) -
Polyfunctional T cells and unique cytokine clusters imprint the anti rAAV2/rAAV9 vector immune response
by: Stephan J. Holtkamp, et al.
Published: (2024-11-01)